Adult T-cell leukemia (also called adult T-cell leukemia/lymphoma, or ATL) is a rare, often aggressive cancer of mature T-lymphocytes caused by long-term infection with human T-cell lymphotropic virus type 1 (HTLV-1). It is diagnosed by combining a positive HTLV-1 antibody test with evidence of a clonal abnormal T-cell population in the blood, lymph nodes, or other tissue. Treatment depends on the subtype and ranges from careful monitoring to intensive chemotherapy and stem cell transplant.
As someone who works in hematology, I find ATL one of the clearest examples of how a virus can drive a blood cancer. Below I explain the cause, the four clinical types, how the diagnosis is made, and where treatment stands.
What Is Adult T-Cell Leukemia?
T-lymphocytes are white blood cells that coordinate immune responses and kill infected cells. In ATL, a single infected CD4-positive T-cell acquires enough changes to grow out of control, producing a clone of malignant cells. These cells circulate in the blood, infiltrate lymph nodes, skin, liver, and spleen, and can also settle in the lungs, gut, and nervous system.
Like many other hematological disorders, ATL spans a spectrum. Some patients have a slow condition for years, while others become seriously ill within weeks.
Where ATL Occurs
HTLV-1 is endemic in southwestern Japan, the Caribbean, parts of Central and South America, sub-Saharan Africa, Iran, and parts of Melanesia and Australia. ATL is therefore concentrated in people who were born in, or have family from, these regions. Elsewhere it is uncommon, which can delay diagnosis.
Causes and Risk Factors
HTLV-1 is a retrovirus, meaning it inserts its genetic material permanently into the DNA of the cells it infects. It is spread through:
- Prolonged breastfeeding from an infected mother, the main route linked to later ATL
- Sexual contact
- Transfusion of cellular blood products from an infected donor
- Sharing needles
Most carriers never develop ATL. The lifetime risk for a carrier is a few percent, and the disease typically appears decades after infection, usually in middle or later adulthood. Infection early in life appears to carry the highest risk.
How the Virus Drives Cancer
Two viral proteins do most of the work. Tax switches on growth signals in infected cells early in the process, while HBZ is expressed continuously and supports cell proliferation and survival. Over many years, infected clones accumulate additional mutations in the host genome, and eventually one clone becomes fully malignant.
The Four Clinical Subtypes
The Shimoyama classification divides ATL into four types. This matters because prognosis and treatment differ sharply between them.
| Subtype | Typical features | Behavior |
|---|---|---|
| Acute | High abnormal lymphocyte count, lymph node and organ involvement, often high calcium and LDH | Aggressive |
| Lymphomatous | Mainly lymph node disease, few abnormal cells in blood | Aggressive |
| Chronic | Raised lymphocyte count, possible skin, liver, or node involvement, normal calcium | Indolent (unfavorable features can make it behave aggressively) |
| Smoldering | Small number of abnormal cells in blood, often with skin or lung lesions, normal lymphocyte count | Indolent |
Indolent types can transform into acute ATL over time, so they need regular follow-up even when a patient feels well.
Symptoms and Complications
Symptoms follow the subtype and the sites involved. Common features include:
- Enlarged lymph nodes, liver, or spleen
- Skin rashes, nodules, or plaques
- Fatigue, fever, weight loss, and night sweats
- Hypercalcemia (high blood calcium), causing thirst, confusion, constipation, and kidney injury
- Lytic bone lesions
- Opportunistic infections, because ATL itself suppresses immunity
Hypercalcemia is a hallmark of aggressive ATL and can be life-threatening, so it is treated as an emergency. Infections such as Pneumocystis pneumonia and strongyloidiasis are well-known risks and often need preventive treatment.
How Adult T-Cell Leukemia Is Diagnosed
Diagnosis rests on three pillars: proof of HTLV-1 infection, proof of an abnormal T-cell population, and staging to assign the subtype.
- Blood count and smear. The smear may show characteristic “flower cells”, lymphocytes with deeply lobulated nuclei shaped like petals.
- HTLV-1 serology. Antibody screening, confirmed by a second test, establishes infection.
- Flow cytometry. ATL cells are usually CD4-positive and CD25-positive and frequently express CCR4, which is also a treatment target.
- Tissue biopsy of a lymph node or skin lesion, especially for the lymphomatous type.
- Blood chemistry, including calcium, LDH, albumin, and kidney function, which help define the subtype.
- Imaging such as CT or PET-CT to map disease, with bone marrow examination in selected cases.
Where needed, testing for monoclonal integration of the HTLV-1 provirus can confirm that the abnormal clone is virus-driven.
Treatment Options
Indolent ATL
For smoldering and favorable chronic ATL, many centers use watchful waiting, treating skin lesions directly as needed. In some regions, the antiviral zidovudine combined with interferon-alpha is used, particularly for leukemic forms. Early chemotherapy has not shown clear benefit in indolent disease.
Aggressive ATL
Acute and lymphomatous ATL need prompt treatment. Options include:
- Combination chemotherapy, such as CHOP-based regimens or more intensive multi-drug protocols
- Mogamulizumab, an antibody targeting CCR4, approved in some countries for ATL
- Zidovudine plus interferon-alpha for selected leukemic presentations
- Supportive care for hypercalcemia and infection prophylaxis
Stem Cell Transplant
Allogeneic hematopoietic stem cell transplant is the only approach that offers long-term disease control for many patients with aggressive ATL. It is considered for younger, fit patients who respond to initial therapy. Because ATL most often affects older adults, only a proportion of patients are eligible.
Prevention and Key Takeaways
Because ATL follows HTLV-1 infection, prevention focuses on stopping transmission. Blood donor screening, avoiding needle sharing, safer sex, and advice on infant feeding for mothers who carry the virus all reduce spread.
- ATL is a T-cell cancer caused by long-standing HTLV-1 infection.
- Only a small minority of carriers develop it, usually decades later.
- The four subtypes range from indolent to highly aggressive.
- Diagnosis combines HTLV-1 serology, flow cytometry, and staging tests.
- Stem cell transplant offers the best chance of long-term control in aggressive disease.
Frequently Asked Questions
If I carry HTLV-1, will I get adult T-cell leukemia?
Most carriers never do. The lifetime risk is a few percent, but carriers should know the warning signs and have medical review if they develop enlarged glands, persistent skin lesions, or unexplained high calcium.
Is adult T-cell leukemia contagious?
The leukemia itself is not contagious, but the HTLV-1 virus that causes it can be passed on through breastfeeding, sexual contact, blood, and shared needles. Carriers can take practical steps to protect partners and children.
What are flower cells?
Flower cells are abnormal lymphocytes with multilobed nuclei that resemble petals. They are a classic finding on the blood smear in ATL, though confirmation needs flow cytometry and HTLV-1 testing.
Can adult T-cell leukemia be cured?
Indolent forms may remain stable for years. Aggressive forms are difficult to cure with chemotherapy alone, and allogeneic stem cell transplant offers the best prospect of long-term remission for eligible patients.
